Latest News

Ceapro Inc. to Present at the 12th International Symposium on Supercritical Fluids

EDMONTON, ALBERTA – April 13, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the 12th International Symposium on Supercritical Fluids

Read more

Ceapro Announces Acceptance of Abstract for Presentation at the Nutrition 2018 Meeting

EDMONTON, ALBERTA – April 3, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that it will present at the American Society for Nutrition’s inaugural flagship

Read more

Ceapro to Present at the Wall Street Investor Forum – Presentation with live webcast on Thursday, March 22nd at 10:20 a.m. ET

EDMONTON, ALBERTA – March 15, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc., MBA, Ceapro’s President and Chief Executive Officer, will

Read more

Ceapro Inc. to Consider Judgements in AVAC Ltd. Actions

EDMONTON, ALBERTA – January 29, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Mr. Justice C.M. Jones issued his written decision with respect to

Read more

Ceapro to Present at Noble Capital Markets’ 14th Annual Investor Conference – Presentation with live video webcast on Tuesday, January 30th at 2:00 p.m. EST

EDMONTON, ALBERTA – January 17, 2018 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon M.Sc., MBA, Ceapro’s President and Chief Executive Officer, will

Read more

Ceapro Announces Grant of Stock Options and Restricted Share Units

EDMONTON, ALBERTA, Canada – January 2, 2018– Ceapro Inc. (TSX-V CZO) today announced the granting of stock options (options) and restricted share units (RSUs) to employees and officers of the Company. Options to purchase 210,000 common shares were granted pursuant to the Company’s Stock Option Plan, with

Read more

Ceapro Reports 2017 Third Quarter Business Update and Financial Results – Recent entry into the cosmeceuticals sector with launch of proprietary line of products – Company continues advancement for expansion into the nutraceutical market – Completion of bio-efficacy study evaluating avenanthramides in exercise-induced inflammation with results expected by year-end – Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q1 2018

EDMONTON, ALBERTA – November 15, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30,

Read more

Ceapro Inc. Announces the Launch of its Proprietary Line of Cosmeceutical Products, JUVENTE – Successful execution of JuventeDC Inc. acquisition marks an important step in Ceapro’s strategic market diversification business plan – New anti-aging skin care product line represents $5B market opportunity and utilizes Ceapro’s active ingredients beta glucan and avenanthramides

EDMONTON, ALBERTA – October 26, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its entry into the end-user cosmeceuticals market through the acquisition of Quebec-based

Read more

Ceapro Reports 2017 Second Quarter Business Update and Financial Results – Continued advancement for expansion into nutraceutical market – Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q4 2017 – Encouraging preliminary data from bio-efficacy study evaluating avenanthramides in exercise-induced inflammation warrant extension to evaluate additional biomarkers

EDMONTON, ALBERTA – August 18, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and six-month periods ended June 30,

Read more

Ceapro Announces Results of 2017 Shareholders’ Meeting

EDMONTON, ALBERTA – June 5, 2017 – Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors, Mr. Gilles Gagnon, Dr. Ulrich Kosciessa, Dr. William

Read more
Page 2 of 1212345...10...Last »